Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial

Evidence from Europe shows that perioperative chemotherapy may be beneficial for the treatment of locally advanced gastric cancer, but reliable and robust data is lacking. To rectify this, the phase 3 RESONANCE trial investigated the efficacy and safety of S-1 plus oxaliplatin (SOX) as a perioperati...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2024-04, Vol.17 (1), p.17-17, Article 17
Main Authors: Wang, Xinxin, Lu, Canrong, Wei, Bo, Li, Shuo, Li, Ziyu, Xue, Yingwei, Ye, Yingjiang, Zhang, Zhongtao, Sun, Yihong, Liang, Han, Li, Kai, Zhu, Linghua, Zheng, Zhichao, Zhou, Yanbing, He, Yulong, Li, Fei, Wang, Xin, Liang, Pin, Huang, Hua, Li, Guoli, Shen, Xian, Ji, Jiafu, Tang, Yun, Xu, Zekuan, Chen, Lin
Format: Article
Language:English
Subjects:
Adjuvant
Adjuvant treatment
Antimitotic agents
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Cancer
Chemotherapy
Chemotherapy, Adjuvant
Complications
Correspondence
Disease-Free Survival
Gastric cancer
Gastrointestinal surgery
Hematology
Humans
Medical centers
Neoadjuvant Therapy
Oxaliplatin
Oxaliplatin - therapeutic use
Patients
Perioperative
Postoperative
Product development
Rankings
S-1
Safety
Stomach cancer
Stomach Neoplasms - drug therapy
Stomach Neoplasms - surgery
Surgery
Toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Evidence from Europe shows that perioperative chemotherapy may be beneficial for the treatment of locally advanced gastric cancer, but reliable and robust data is lacking. To rectify this, the phase 3 RESONANCE trial investigated the efficacy and safety of S-1 plus oxaliplatin (SOX) as a perioperative chemotherapy regimen for gastric cancer. This randomized, open-label trial enrolled patients from 19 medical centers with stage II/III resectable gastric cancer who were centrally randomly assigned to either perioperative chemotherapy (PC) arm or adjuvant chemotherapy (AC) arm. Patients in the PC arm received two to four cycles of SOX followed by surgery and four to six cycles of SOX. Patients in the AC arm received upfront surgery and eight cycles of SOX. 386 patients in each group were enrolled and 756 (382 in PC and 374 in AC) were included in the mITT population. The three-year DFS rate was 61.7% in the PC arm and 53.8% in the AC arm (log-rank p = 0.019). The R0 resection rate in the PC arm was significantly higher than that in the AC arm (94.9% vs. 83.7%, p 
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-024-01536-7